Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Phase I study examining PI 3 kinase inhibitor for various tumours

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.10.12
Views: 3823

Dr Pamela Munster – University of California, San Francisco, USA

Dr Pamela Munster talks to ecancer at the 2012 ESMO congress in Vienna about a phase I study that examined a PI 3 kinase inhibitor across numerous tumour types.


The study aimed to use this inhibitor in a predefined population, using a standard 3+3 design. 175 patients enrolled in the study with kidney, lung, endometrial, breast and bladder cancers. 30% had different varieties of tumours.


Results from the study showed that administering the drug once a day was not optimal and many patients’ dosages were increased, as well as a few patients receiving more than the established maximum dosage. The largest efficacy was seen in kidney and bladder cancers.


Dr Munster explains that further research needs to be done in identifying biomarkers and understanding patient responses.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation